Can a supplement like creatine boost mental health when added to therapy?

A 2025 systematic review and meta-analysis pooling data from 11 randomized trials—including 1,093 participants—found that creatine supplementation was associated with a mean reduction of 2.2 points in depressive symptoms measured on the 17-item Hamilton Depression Rating Scale. That figure falls short of the three-point difference widely regarded as the minimum clinically important threshold.

The researchers assigned “very low” certainty to the overall evidence and highlighted substantial heterogeneity across the included studies. Their final conclusion emphasized caution: the true effect size could be negligible or even zero. This finding places creatine in a distinct category—not as an established antidepressant, but as a biologically plausible candidate requiring further validation through larger, longer-duration clinical trials.

How Creatine Interacts With Brain Energy Metabolism

Creatine plays a central role in cellular energy homeostasis by supporting the regeneration of adenosine triphosphate (ATP), the primary energy currency of cells. Though skeletal muscle stores the majority of the body’s creatine, the brain maintains its own independent creatine system. Given the organ’s exceptionally high metabolic demands, scientists have theorized that modulating brain creatine availability might influence mood regulation and cognitive function.

This hypothesis underpins growing interest in creatine within psychiatric research. A 2024 literature review outlined potential mechanisms linking creatine to depression, including effects on brain energy metabolism and neuroplasticity. However, the review also underscored the absence of robust clinical trial data capable of confirming those theoretical pathways.

Adjunctive Use Shows More Promise Than Monotherapy

Trials investigating creatine as a standalone intervention for depression have yielded inconclusive results. In contrast, studies examining its use alongside existing treatments report more encouraging signals. One 2025 double-blind, placebo-controlled pilot trial tested oral creatine monohydrate as an add-on to cognitive behavioral therapy (CBT) in an under-resourced setting. The eight-week feasibility study suggested creatine may enhance CBT response, though the authors explicitly labeled their findings as hypothesis-generating and stressed the need for expanded follow-up research before definitive conclusions can be drawn.

This distinction is critical: if future evidence supports clinical utility, creatine’s likely role would be adjunctive—not as a replacement for first-line therapies, but as a potential enhancer of their effectiveness.

Regulatory Assessment Highlights Evidence Gaps

The European Food Safety Authority issued a 2024 evaluation concluding that current data are insufficient to establish a cause-and-effect relationship between creatine supplementation and improved cognitive function. That determination does not rule out biological activity; rather, it reflects inconsistencies in outcomes across trials—differences potentially attributable to variations in participant characteristics, testing conditions, baseline creatine status, dietary intake, or physiological stressors such as sleep deprivation or aging.

No consensus exists on whether these variables meaningfully moderate creatine’s effects on cognition. Their influence remains speculative pending targeted investigation.

Creatine occupies an unusual position among mental health–targeted supplements: it has undergone extensive safety evaluation and demonstrates good tolerability at appropriate doses. Yet its well-documented safety profile does not strengthen the evidentiary foundation for mental health applications. Similarly, perceived acceptability—particularly among individuals reluctant to use psychiatric medications due to stigma—does not substitute for clinical validation.

Current evidence indicates modest potential benefit for depression when used adjunctively, while findings on cognition remain inconsistent. These observations justify continued research—but do not support positioning creatine as a treatment for depression or as a general cognitive enhancer. The boundary between promising preliminary data and clinically actionable intervention remains firmly intact.